CaMKIIδ Inhibitors
The class of CaMKIIδ inhibitors comprises a diverse array of chemicals designed to either directly antagonize the kinase or indirectly modulate its activity through intricate signaling pathways. KN-93, an exemplary direct inhibitor (CAS Number: 139298-40-1), specifically targets CaMKIIδ by binding to its calmodulin-binding domain, preventing autophosphorylation, and hindering its kinase activity. AIP (CAS Number: 138047-89-3), another direct inhibitor, mimics the autoinhibitory domain of CaMKII, competitively impeding substrate interaction and offering insights into the intricate regulation of CaMKIIδ. Beyond direct inhibition, compounds like H89 (CAS Number: 130964-39-5) exemplify the indirect modulation of CaMKIIδ by targeting the cAMP/PKA pathway.
By inhibiting PKA, H89 influences phosphorylation events that can impact CaMKIIδ, revealing the intricate crosstalk between signaling pathways. Nifedipine (CAS Number: 21829-25-4), a calcium channel blocker, represents an indirect inhibitor altering calcium dynamics to impact CaMKIIδ activation, emphasizing the role of calcium signaling in regulating kinase activity. The versatility of this class is further highlighted by compounds like Staurosporine (CAS Number: 62996-74-1), a broad-spectrum kinase inhibitor, impacting CaMKIIδ indirectly by affecting multiple kinase pathways. TBB (CAS Number: 548472-68-0), a CK2 inhibitor, showcases indirect modulation by altering phosphorylation events through the CK2 signaling axis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93, a CaMKII inhibitor, directly targets and inhibits CaMKIIδ. By binding to the calmodulin-binding domain of CaMKII, KN-93 prevents its autophosphorylation and activation, thereby impeding the kinase activity of CaMKIIδ. This direct inhibition strategy makes KN-93 a specific and potent antagonist of CaMKIIδ, offering insights into potential therapeutic interventions for conditions associated with dysregulated CaMKIIδ activity. | ||||||
Aluminum isopropoxide | 555-31-7 | sc-239217 | 100 g | $37.00 | ||
Autocamtide-2-related inhibitory peptide (AIP) serves as a direct inhibitor of CaMKIIδ by mimicking the autoinhibitory domain of CaMKII. AIP competes with endogenous CaMKII substrates, preventing their interaction with the kinase. This mechanism results in the suppression of CaMKIIδ activity, illustrating a direct inhibition approach that holds promise for investigating the physiological consequences of modulating CaMKIIδ in various cellular contexts. | ||||||
KN-92 | 1135280-28-2 | sc-311369 sc-311369A | 1 mg 5 mg | $182.00 $561.00 | 7 | |
KN-92, a structural analog of KN-93, functions as a direct inhibitor of CaMKIIδ by interfering with its autophosphorylation and subsequent activation. Similar to KN-93, KN-92 binds to the calmodulin-binding domain of CaMKII, disrupting the kinase's ability to undergo autophosphorylation. This direct interaction with CaMKIIδ positions KN-92 as a valuable tool for probing the functional consequences of CaMKIIδ inhibition in cellular and molecular processes. | ||||||
Naphthol AS | 92-77-3 | sc-215536A sc-215536 | 25 g 500 g | $41.00 $159.00 | ||
Naphthol AS-E phosphate, a chromogenic substrate for phosphatases, serves as an indirect inhibitor of CaMKIIδ by influencing its dephosphorylation. In cellular contexts, phosphatases can dephosphorylate and inactivate CaMKIIδ. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $133.00 | 20 | |
KN-62, a cell-permeable inhibitor, acts as a direct antagonist of CaMKIIδ by binding to its ATP-binding site. This binding prevents ATP from accessing the kinase domain, inhibiting CaMKIIδ autophosphorylation and subsequent activation. | ||||||
Compound 48/80 trihydrochloride | 94724-12-6 | sc-200736 sc-200736A sc-200736B sc-200736C | 100 mg 250 mg 1 g 5 g | $102.00 $214.00 $826.00 $3682.00 | ||
Compound 48/80, a mast cell degranulator, serves as an indirect inhibitor of CaMKIIδ by influencing calcium signaling. By inducing calcium release from intracellular stores, Compound 48/80 can activate CaMKIIδ indirectly through the elevation of cytosolic calcium levels. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, acts as an indirect inhibitor of CaMKIIδ by modulating the PI3K/AKT pathway. By inhibiting PI3K, Wortmannin suppresses AKT activation, influencing downstream signaling events that indirectly impact CaMKIIδ activity. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $153.00 $600.00 | 27 | |
Calmidazolium chloride, a calmodulin antagonist, acts as an indirect inhibitor of CaMKIIδ by disrupting the interaction between calmodulin and CaMKII. Calmidazolium chloride prevents calmodulin from binding to CaMKII, indirectly inhibiting CaMKIIδ activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, serves as an indirect inhibitor of CaMKIIδ by modulating calcium influx. By inhibiting L-type calcium channels, Nifedipine reduces intracellular calcium levels, indirectly impacting CaMKIIδ activation. The indirect modulation of CaMKIIδ by Nifedipine through alterations in calcium dynamics offers a perspective on the potential consequences of disrupting calcium signaling pathways on CaMKIIδ activity in various cellular contexts. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, acts as an indirect inhibitor of CaMKIIδ by affecting multiple kinase pathways. While not specific to CaMKIIδ, Staurosporine's inhibition of kinases in the cellular milieu can indirectly impact CaMKIIδ activity. | ||||||